Compare Adaptive Biotechnologies Corp (ADPT) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Schwab US Large Cap Growth ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.45 (market cap $4.02B), while Schwab US Large Cap Growth ETF trades at $35.94. Which is the better fit depends on your goals.
| ADPT | SCHG | |
|---|---|---|
Market Cap | $4.02B | — |
Sector | Health | Sector/Thematic |
52-Week High | $25.45 | $35.83 |
52-Week Low | $12.30 | $28.10 |
Enterprise Value | $4.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.46, down 3.66% today but remains near its 52-week high. The stock shows bullish technical signals with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025, while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to a pure-play MRD diagnostics business following the Immune Medicine separation has generated positive investor sentiment, with 65% of analysts maintaining buy ratings.
Outlook remains cautiously optimistic as ADPT's MRD business demonstrates strong growth potential with 49% YoY revenue expansion. Key risks include persistent negative profitability metrics and execution challenges during the business separation. The consensus price target of $25.50 suggests modest upside potential from current levels, contingent on continued operational improvement.
SCHG trades at $35.61, showing minimal daily movement (-0.11%) amid a bullish technical outlook with strong moving average signals. The ETF's concentrated portfolio in large-cap growth stocks, particularly technology leaders, drives performance but introduces concentration risk. Recent news highlights SCHG's strong historical returns and low 0.04% expense ratio as key advantages for long-term investors.
The outlook remains positive given SCHG's exposure to AI and technology growth trends, though elevated RSI levels suggest potential near-term consolidation. Risks include heavy reliance on top holdings and sensitivity to interest rate changes. Analyst sentiment is generally favorable for long-term growth exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
